BiotechTube

CB-5945 + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid-Induced Constipation

Conditions

Opioid-Induced Constipation

Trial Timeline

May 20, 2013 → Feb 13, 2014

NCT ID
NCT01901302

About CB-5945 + Placebo

CB-5945 + Placebo is a phase 3 stage product being developed by Merck for Opioid-Induced Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01901302. Target conditions include Opioid-Induced Constipation.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT01901341Phase 3Terminated
NCT01901302Phase 3Terminated
NCT01901328Phase 3Terminated
NCT01696643Phase 3Terminated

Competing Products

20 competing products in Opioid-Induced Constipation

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
NaloxegolKyowa KirinPre-clinical
23
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
NKTR-118 + Usual careAstraZenecaPhase 3
77
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + Placebo Oral CapsuleAstraZenecaPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Methylnaltrexone bromide + PlaceboPfizerPhase 2
51
ALKS 37 + PlaceboAlkermesPhase 2
49

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85